Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation

Core Viewpoint - Harmony Biosciences Holdings, Inc. reported strong preliminary, unaudited net product revenue for Q4 and full year 2025, indicating continued growth and profitability in the biotech sector [1] Financial Performance - The company announced Q4 2025 net product revenue of approximately $243 million [1] - Full year 2025 net product revenue reached approximately $868 million [1] - Harmony has achieved six consecutive years of revenue growth, demonstrating a solid financial trajectory [1] Business Strategy - Harmony is on track to extend the pitolisant franchise, which is a key component of its product portfolio [1] - The company is positioning itself as a profitable, self-funding biotech entity with a robust late-stage pipeline [1] - Strong long-term growth prospects are highlighted, reinforcing the company's strategic direction [1]